Recent clinical trials in ovarian cancer, which includes PARP inhibitors in combination with Bevacizumab or chemotherapy, have shown promising results in terms of overall all survival and progression-free survival [164, 169–171]. This evidence concerns the gene PARP1 and ovarian cancer.